Texas is on the brink of launching the most ambitious state-backed psychedelic research initiative in U.S. history. A proposed $50 million public-private partnership aims to fund FDA-approvable clinical trials of ibogaine, a psychedelic compound known for its potential to treat opioid addiction and other mental health conditions. While supporters are hailing this as a breakthrough, critics have raised questions about equity, safety, and scientific rigor.
How Texas Took the Lead on Psychedelic Research
The plan to fund ibogaine research in Texas stems largely from Bryan Hubbard, former chair of Kentucky’s Opioid Abatement Advisory Commission. After failed attempts to secure funding in Kentucky, Ohio, and South Dakota, Hubbard received a call from Texas in late 2024. With a nearly $20 billion budget surplus and previous experience passing psychedelic legislation, the state was ready to listen.
With support from former Texas Governor Rick Perry, GOP strategist Rex Elsass, and mental health advocates, the proposal gained momentum. Two bills—SB 2308 and HB 3717—were fast-tracked through the Texas legislature, clearing both chambers. Final details are now being negotiated in a conference committee before the legislation heads to Governor Greg Abbott.
What the Ibogaine Bill Proposes
If signed into law, the legislation would go into effect on September 1, 2025. A grant program under the Health and Human Services Commission would invite research proposals focused on FDA-approvable ibogaine treatments. Applicants would need to:
- Provide a full drug development plan
- Seek FDA approval for clinical trials
- Address how Texas could benefit from intellectual property rights
- Propose strategies for making treatments accessible to uninsured patients
Grant recipients would be selected by a committee that includes experts, funders, and lawmakers. The full application process could begin later this year, with proposals due no earlier than 90 days after the launch.
Hype Meets Hesitation: Safety, Access, and Overselling
While the proposal has stirred optimism among advocates, many experts and observers urge caution. Ibogaine therapy is complex and resource-intensive, often requiring multi-day clinical monitoring due to potential cardiac risks. Treatments can cost up to $50,000, and scalable models remain largely undeveloped.
Advocates, including Rick Perry, have made sweeping claims about ibogaine’s power to heal. However, clinicians and researchers stress that current data remains limited, particularly in areas like traumatic brain injury and Parkinson’s disease. Concerns have also been raised that public enthusiasm may be outpacing clinical evidence.
Questions of Ethics and Equity
A major point of contention is the lack of engagement with Bwiti elders and Gabonese communities, who have used the iboga plant for generations in spiritual and medicinal contexts. Critics, including ibogaine researchers and activists like Dr. Joseph Barsuglia, argue that the initiative risks repeating patterns of biopiracy and ignores the need for benefit-sharing with Indigenous knowledge holders.
Although Texas officials say they are open to involving traditional communities in the process, the legislation itself does not mandate such inclusion. This has sparked concerns over the ethical foundations of the initiative, especially in light of international agreements like the Nagoya Protocol, which the U.S. has not signed.
Can Texas Make It Work?
Advocates of the Texas initiative say their goal is clear: make ibogaine therapy accessible, equitable, and scientifically validated. But they acknowledge the road ahead is uncertain. The infrastructure, costs, and safety hurdles are significant, and questions remain about how the state will ensure access to underserved populations.
If successful, Texas could become a blueprint for other states considering similar efforts. Already, representatives from 15 states attended a recent ibogaine meeting in Aspen, and talks of a national coalition are underway.
What Happens Next?
Once the legislative differences are resolved, the final bill will move to Governor Abbott for approval. If he signs, the call for grant applications will begin this fall, and full-scale clinical trials could be underway within the next two years.
Despite the many unanswered questions, one thing is clear: Texas is attempting something no other state has done—using public funds to jumpstart psychedelic drug development at a massive scale. Whether this bold bet pays off remains to be seen.

